Clinical Trial Update: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) [Phase 3]

View source ↗

Summary

Phase 3 trial ODYSSEY HIGH FH evaluated alirocumab added to lipid-modifying therapy versus placebo in patients with heterozygous familial hypercholesterolemia, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia

Drugs mentioned

• Repatha (alirocumab) (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolaemia | Phase 3 | Status: COMPLETED | Results posted: 2015-11-06